Novartis v Roche: Bondronat leavepiece—misleading indirect comparisons and renal safety messaging (AUTH/2199/1/09)

📊

Key facts

⌄

Case	AUTH/2199/1/09
Parties	Novartis v Roche Products Limited
Medicine / material	Bondronat (ibandronate) promotional leavepiece (ref P116532)
Comparator mentioned	Zometa (zoledronic acid); also pamidronate and placebo in cited graphs
Audience / use	Hospital sales force with clinical and medical oncologists (consultants and specialist registrars) and breast care nurses
Key issues	Misleading indirect cross-trial comparison graphs; exaggerated renal safety reassurance claim; misleading use of interim poster/observational data; lack of clarity on oral vs IV; misleading “minimal risk/good safety profile” statements
Applicable Code year	2008
Complaint received	13 January 2009
Case completed	04 March 2009
Appeal	No appeal
Breach clauses	7.2 (x6), 7.3 (x3), 7.4, 7.8, 7.10, 9.1
No breach clauses	2, 8.1; 7.9 not breached (Panel reminder requested)
Sanctions	Undertaking received; additional sanctions not stated

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

Novartis complained about an 8-page Roche promotional leavepiece for Bondronat (ibandronate), used by the hospital sales force with oncologists and breast care nurses, comparing against zoledronic acid (Zometa).
Page 3 presented three stacked graphs (from a review article) aligned on the same hazard ratio axis, creating an implied direct comparison across different trials with different primary endpoints and missing study references on the page.
Page 4 headline claim: “Bondronat gives you renal safety reassurance”, supported by multiple references and an interim observational poster (Meden et al) with comparative statements.
Page 5 used interim poster data (Houston et al) about renal monitoring/overdosing, without clearly stating it compared IV zoledronic acid with oral ibandronate and without differentiating oral vs IV Bondronat in claims.
Page 7 included claims such as “With minimal risk of renal function concerns” and “Time to show a good safety profile”, in a context suggesting Bondronat could be used irrespective of renal function.
Novartis also alleged the leavepiece disparaged zoledronic acid (Clause 8.1) and was so serious it breached Clause 2; these were not upheld.

⚖️

⌄

Breach found: the cross-trial graph presentation was misleading/unbalanced and did not maintain high standards.
Breach found: “Bondronat gives you renal safety reassurance” was misleading, exaggerated, not substantiated, and did not promote rational use.
Breach found: Meden et al interim observational poster data were presented misleadingly (study incomplete, no stats, unclear matching), and this was not stated.
Breach found: Houston et al interim poster data were presented misleadingly, including lack of clarity on oral vs IV and interim nature/no statistical analysis.
Breach found: Page 7 claims “With minimal risk of renal function concerns” and “Time to show a good safety profile” were misleading in context.
No breach: Clause 8.1 (disparagement) not upheld overall.
No breach: Clause 2 (bringing discredit) not upheld.
No breach: Clause 7.9 (use of “safe/safety”) not ruled as breached, but the Panel asked that both parties be reminded of Clause 7.9 requirements.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access